IL6 and myocardial infarction: The group receiving this treatment had improved cardiac contractility at 5 weeks post myocardial infarction and enhanced blood vessel density in the border zone of the infarct, decreased interstitial fibrosis, and reduced levels of the plasma pro-inflammatory cytokines (IL-6 and TNF-α).